

27. A compound, tautomer or pharmaceutically acceptable salt as defined in any one of claims 1-25, for use as a medicament.

28. ~~A method for inhibiting BTK in a subject, the method comprising administering to the subject~~ Use of a compound, tautomer or pharmaceutically acceptable salt as defined in any one of claims 1-25 in the manufacture of a medicament for inhibiting BTK in a subject.

29. ~~A method of treating a disease, disorder or condition in a subject, the method comprising administering to the subject an effective amount of~~ Use of a compound, tautomer or pharmaceutically acceptable salt as defined in any one of claims 1-25 in the manufacture of a medicament for treating, wherein the a disease, disorder or condition is associated with BTK in a subject.

30. ~~A method of treating a disease, disorder or condition in a subject, the method comprising administering to the subject an effective amount of~~ Use of a compound, tautomer or pharmaceutically acceptable salt as defined in any one of claims 1-25 in the manufacture of a medicament for treating, wherein the a disease, disorder or condition is selected from Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, and non-malignant proliferative disorders in a subject.

31. ~~A method of treating a disease, disorder or condition in a subject, the method comprising administering to the subject an effective amount of~~ Use of a compound, tautomer or pharmaceutically acceptable salt as defined in any one of claims 1-25 in the manufacture of a medicament for treating, wherein the a disease, disorder or condition is selected from allergic rhinitis, asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, Sjögren's syndrome, ankylosing spondylitis, Behcet's disease, graft versus host disease, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, and thrombosis in a subject.

32. ~~A method of treating a disease, disorder or condition in a subject, the method comprising administering to the subject an effective amount~~ Use of a compound, tautomer or pharmaceutically acceptable salt as defined in any one of claims 1-25 in the manufacture of a medicament for treating a, wherein the disease, disorder or condition is selected from B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma in a subject.